BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Skorska A, Müller P, Gaebel R, Große J, Lemcke H, Lux CA, Bastian M, Hausburg F, Zarniko N, Bubritzki S, Ruch U, Tiedemann G, David R, Steinhoff G. GMP-conformant on-site manufacturing of a CD133+ stem cell product for cardiovascular regeneration. Stem Cell Res Ther 2017;8:33. [PMID: 28187777 DOI: 10.1186/s13287-016-0467-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ten Ham RMT, Nievaart JC, Hoekman J, Cooper RS, Frederix GWJ, Leufkens HGM, Klungel OH, Ovelgönne H, Hoefnagel MHN, Turner ML, Mountford JC. Estimation of manufacturing development costs of cell-based therapies: a feasibility study. Cytotherapy 2021;23:730-9. [PMID: 33593688 DOI: 10.1016/j.jcyt.2020.12.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
2 Müller-Ruch U, Skorska A, Lemcke H, Steinhoff G, David R. GLP: A requirement in cell therapies - perspectives for the cardiovascular field. Adv Drug Deliv Rev 2020;165-166:96-104. [PMID: 32305352 DOI: 10.1016/j.addr.2020.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Sasse S, Skorska A, Lux CA, Steinhoff G, David R, Gaebel R. Angiogenic Potential of Bone Marrow Derived CD133+ and CD271+ Intramyocardial Stem Cell Trans- Plantation Post MI. Cells 2019;9:E78. [PMID: 31892273 DOI: 10.3390/cells9010078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
4 Sadraddin H, Gaebel R, Skorska A, Lux CA, Sasse S, Ahmad B, Vasudevan P, Steinhoff G, David R. CD271+ Human Mesenchymal Stem Cells Show Antiarrhythmic Effects in a Novel Murine Infarction Model. Cells 2019;8:E1474. [PMID: 31757119 DOI: 10.3390/cells8121474] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Oztel ON, Korkmaz S, Karaoz E. Determination of antibiotic impurities in good manufacturing practices-grade cell therapy medicinal products. Prep Biochem Biotechnol 2020;50:156-63. [PMID: 31631751 DOI: 10.1080/10826068.2019.1676780] [Reference Citation Analysis]
6 Laschke MW, Heß A, Scheuer C, Karschnia P, Kontaxi E, Menger MD. University of Wisconsin solution for the xeno-free storage of adipose tissue-derived microvascular fragments. Regenerative Medicine 2019;14:681-91. [DOI: 10.2217/rme-2018-0164] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Erdmann M, Uslu U, Wiesinger M, Brüning M, Altmann T, Strasser E, Schuler G, Schuler-Thurner B. Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy. J Immunol Methods 2018;463:89-96. [PMID: 30266448 DOI: 10.1016/j.jim.2018.09.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
8 Hausburg F, Müller P, Voronina N, Steinhoff G, David R. Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting. J Vis Exp 2018. [PMID: 29985305 DOI: 10.3791/57474] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Pörtner R, Parida SK, Schaffer C, Hoffmeister H. Landscape of Manufacturing Process of ATMP Cell Therapy Products for Unmet Clinical Needs. Stem Cells in Clinical Practice and Tissue Engineering 2018. [DOI: 10.5772/intechopen.69335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
10 Lemcke H, Voronina N, Steinhoff G, David R. Recent Progress in Stem Cell Modification for Cardiac Regeneration. Stem Cells Int 2018;2018:1909346. [PMID: 29535769 DOI: 10.1155/2018/1909346] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 9.6] [Reference Citation Analysis]
11 Tarnowski J, Krishna D, Jespers L, Ketkar A, Haddock R, Imrie J, Kili S. Delivering advanced therapies: the big pharma approach. Gene Ther 2017;24:593-8. [PMID: 28737744 DOI: 10.1038/gt.2017.65] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Stamm C. Successful, neutral, or negative? J Thorac Cardiovasc Surg 2017;154:555. [PMID: 28724240 DOI: 10.1016/j.jtcvs.2017.03.091] [Reference Citation Analysis]
13 Müller P, Gaebel R, Lemcke H, Steinhoff G, David R. Data on the fate of MACS® MicroBeads intramyocardially co-injected with stem cell products. Data Brief 2017;13:569-74. [PMID: 28706966 DOI: 10.1016/j.dib.2017.06.035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
14 Müller P, Gaebel R, Lemcke H, Wiekhorst F, Hausburg F, Lang C, Zarniko N, Westphal B, Steinhoff G, David R. Intramyocardial fate and effect of iron nanoparticles co-injected with MACS® purified stem cell products. Biomaterials 2017;135:74-84. [PMID: 28494265 DOI: 10.1016/j.biomaterials.2017.05.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]